Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.47 |
| ▸ | BCL2 | P10415 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18362178 | 0.81 | HTR6 (0.44) | HTR6MCL1BCHE | |
| SCHEMBL7958584 | 0.81 | HTR6 (0.50) | HTR6ROCK1MCL1BCL2MAPT | |
| SCHEMBL4323501 | 0.80 | HTR6 (0.52) | HTR6ROCK1MCL1BCL2MAPT | |
| SCHEMBL6384688 | 0.80 | MCL1 (0.51) | HTR6ROCK1MCL1BCL2 | |
| SCHEMBL23956093 | 0.80 | HTR2C (0.56) | HTR6ROCK1MCL1BCL2MAPT | |
| SCHEMBL18049242 | 0.79 | HTR6 (0.67) | HTR6ROCK1MCL1BCL2MAPT | |
| SCHEMBL6384954 | 0.79 | MCL1 (0.50) | HTR6ROCK1MCL1BCL2MAPT | |
| SCHEMBL4333782 | 0.78 | HTR6 (0.46) | HTR6ROCK1MCL1BCL2BCHE | |
| SCHEMBL27587757 | 0.78 | MCL1 (0.54) | HTR6ROCK1MCL1BCL2 | |
| SCHEMBL4328875 | 0.78 | HTR6 (0.52) | HTR6ROCK1MCL1BCL2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | HTR6 2732/4885ROCK1 1941/4885MCL1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.